Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
Charles River Laboratories International, Inc. logo

NYSE · CRL

Charles River Laboratories International, Inc.

Healthcare · Medical - Diagnostics & Research

$304.96

Down-$5.81 (-1.87%)

Updated Oct 7, 2026, 7:50 AM

SID Score

6.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.57B
P/E ratio
-137.99
Dividend yield
0.00%
52-week range
$146.20 – $312.26
Volume
1.92M
Avg. volume
1.03M

Price performance · CRL

CRL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CRL closed at $304.96 after 21 trading sessions, up 8.62% for the selected period.

Last close
$304.96
Period change
+8.62%
Period low
$272.88
Period high
$310.77
Daily close
View OHLC price history
CRL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$319.80$333.295$300.01$304.961.92M
Oct 5, 2026$292.05$312.26$292.02$310.771.31M
Oct 2, 2026$287.91$290.6125$285.75$290.19445.52K
Oct 1, 2026$291.86$297.00$284.6106$286.83823.07K
Sep 30, 2026$296.97$298.9839$293.455$295.01799.36K
Sep 29, 2026$294.71$298.20$289.38$295.96661.45K
Sep 28, 2026$289.13$296.8825$289.13$294.59901.74K
Sep 25, 2026$293.19$295.2276$287.2348$292.84838.26K
Sep 24, 2026$277.00$298.40$276.95$294.441.59M
Sep 23, 2026$283.85$291.09$276.64$277.331.59M
Sep 22, 2026$280.19$290.11$277.41$285.111.14M
Sep 21, 2026$279.37$281.63$275.88$279.01952.93K
Sep 18, 2026$281.26$282.995$276.00$278.061.48M
Sep 17, 2026$280.11$285.5775$274.40$281.67809.84K
Sep 16, 2026$272.78$282.905$270.88$273.411.01M
Sep 15, 2026$272.27$276.09$269.93$272.88983.75K
Sep 14, 2026$278.27$279.64$267.27$273.111.39M
Sep 11, 2026$276.01$280.40$275.63$278.26767.56K
Sep 10, 2026$275.38$275.88$272.0599$273.00764.68K
Sep 9, 2026$278.54$280.745$275.00$278.35789.22K
Sep 8, 2026$285.60$285.94$280.1584$280.76729.16K

Latest CRL news

The latest Smart Investors Daily articles mentioning CRL.

Stock researchCompany · Overview

CRL research

Overview

Company profile and research snapshot.

Company profile

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$191.50
Implied upside
—
Analysts
22
CRL recent ratings
DateFirmRatingTarget
Sep 30, 2026UBSBuy—
Sep 28, 2026JefferiesBuy—
Sep 25, 2026Deutsche BankBuy—
Sep 25, 2026Evercore ISI GroupOutperform—
Sep 25, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases

Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...

Yahoo · Sep 30, 2026

Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory

Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Animal Model - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By